ArticlePloS one2013
The peripheral myeloid expansion driven by murine cancer progression is reversed by radiation therapy of the tumor.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 43 citations in OpenAlex.
- Anti-CSF-1R therapy with combined immuno-chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched triple negative breast cancers.Nature communications · 2026Article
- Tumor associated neutrophils promote prostate cancer progression by mediating neutrophil trap secretion through PSMA1- NF-κB-HIF-1α signaling axis.Frontiers in immunology · 2025Article
- Strategies for overcoming tumour resistance to immunotherapy: harnessing the power of radiation therapy.The British journal of radiology · 2024Review
- Tumor resident memory CD8 T cells and concomitant tumor immunity develop independently of CD4 help.Scientific reports · 2023Article
- Galectin-3 inhibition with belapectin combined with anti-OX40 therapy reprograms the tumor microenvironment to favor anti-tumor immunity.Oncoimmunology · 2021Article
- Review
- Blockade of fibroblast activation protein in combination with radiation treatment in murine models of pancreatic adenocarcinoma.PloS one · 2019Article
- Exploring the rationale for combining ionizing radiation and immune checkpoint blockade in head and neck cancer.Head & neck · 2018Review
- Tumor cure by radiation therapy and checkpoint inhibitors depends on pre-existing immunity.Scientific reports · 2018Article
- Proton beam therapy and immunotherapy: an emerging partnership for immune activation in non-small cell lung cancer.Translational lung cancer research · 2018Review
- The Impact of Radiation on the Tumor Microenvironment: Effect of Dose and Fractionation Schedules.Cancer growth and metastasis · 2018Review
- Immunomodulation of the Tumor Microenvironment: Turn Foe Into Friend.Frontiers in immunology · 2018Review
- Radiotherapy and immunotherapy: a beneficial liaison?Nature reviews. Clinical oncology · 2017Review
- A Century of Radiation Therapy and Adaptive Immunity.Frontiers in immunology · 2017Review
- STING expression and response to treatment with STING ligands in premalignant and malignant disease.PloS one · 2017Article
- Modulating Both Tumor Cell Death and Innate Immunity Is Essential for Improving Radiation Therapy Effectiveness.Frontiers in immunology · 2017Review
- Immunological off-target effects of imatinib.Nature reviews. Clinical oncology · 2016Review
- A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pancreatic adenocarcinoma.Journal for immunotherapy of cancer · 2016Article
- Radiotherapy Combined with Novel STING-Targeting Oligonucleotides Results in Regression of Established Tumors.Cancer research · 2016Article
- Optimizing Timing of Immunotherapy Improves Control of Tumors by Hypofractionated Radiation Therapy.PloS one · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Expansion of myeloid-lineage leukocytes in tumor-bearing mice has been proposed as a cause of systemic immunosuppression. We demonstrate that radiation therapy of tumors leads to a decline in myeloid cell numbers in the blood and a decrease in spleen size. The frequency of myeloid cells does not decline to the level seen in tumor-free mice: we demonstrate that metastatic disease can prevent myeloid cell numbers from returning to baseline, and that tumor recurrence from residual disease correlates with re-expansion of myeloid lineage cells. Radiation therapy results in increased proliferation of T cells in the spleen and while T cell responses to foreign antigens are not altered by tumor burden or myeloid cell expansion, responses to tumor-associated antigens are increased after radiation therapy. These data demonstrate that myeloid cell numbers are directly linked to primary tumor burden, that this population contracts following radiation therapy, and that radiation therapy may open a therapeutic window for immunotherapy of residual disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.